Clinical Trial Details

NCT ID: NCT01293838
Date Last Changed: February 10, 2011

Overview

Research Study Summary

A Phase 1 clinical study for patients with Anxiety Disorder

Research Study Title

Cipralex® for Anxiety Disorders in Adolescents: Clinical and Physiological Changes Associated With Open Label, Flexible-dose Treatment

Purpose

The primary objective is to examine whether Cipralex® is effective and safe in the treatment of anxiety disorders in youth. The secondary objective is to identify changes in arousal and stress response from pre- to post-treatment with Cipralex® in youth with anxiety disorders.

To Learn more

Recruitment Details

Phase
1
Gender
Both Male and Female
Age
13 to 18 Years
Overall Status
Recruiting
Lead Sponsor
University of Ottawa
Duration
46 Months
Facility Type
N/A
Compensation

Eligibility

Both Male and Female ages 13 Years to 18 Years

Inclusion Criteria:

  • Primary diagnosis of (1 or more)

  • Social Phobia

  • Generalized Anxiety Disorder

  • Separation Anxiety Disorder

  • Panic Disorder

  • Comorbid depression allowed

Exclusion Criteria:

  • Unstable medical condition

  • Substance use disorder

  • Current diagnosis of OCD

  • Lifetime diagnosis of developmental delay, pervasive developmental disorder, psychosis

Site Locations (1)

Country State City Zip Facility and Contact
Canada Ontario Ottawa K1Z 7K4 The University of Ottawa Institute of Mental Health Research
Chantelle McEwen, MA
613-722-6521 ext. 6194
chantelle.mcewen@rohcg.on.ca

Martine Flament, MD
Principal Investigator

Contact

Martine Flament, MD
613-722-6521 ext. 6455
E-mail:

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.